What to expect as the virus continues

--  |   08/04/2020 Text size  Decrease  Increase   |  
<p>As the coronavirus continues to spread and impact both the health of humanity and the economy, our healthcare strategist, Karen Andersen, sat down with director of personal finance Christine Benz to share her analysis of the impacts and government response. More states have issued stay-at-home orders, and more than 100,000 tests are being performed every day in efforts to reduce the number of cases as well as restrictions. A recent&nbsp;<a href="https://www.morningstar.com/articles/971254/morningstars-view-the-impact-of-coronavirus-on-the-economy">paper by Andersen and equity analyst Preston Caldwell</a>&nbsp;highlights several treatments in clinical trials for an effective treatment for the virus.&nbsp;&nbsp;<br /><br />While the waves of the virus and social distancing measures are projected to continue into the second half of the year, the economic impact is not expected to be long term. Maintaining social distancing measures to contain the virus is the main priority--along with the ability to use various apps to track the locations of people who have contracted the virus. Technology is imperative during the quarantine as businesses work remotely and research on the virus continues. On that same note, limitations are present: the shortage of ventilators and beds in the ICU. Companies are trying to respond quickly to increase capacity, but it is likely that the virus may overlap them. The worst wave is expected to hit in April. Improvement at the beginning of May can be expected if social distancing orders are obeyed, possible treatments continue to be tested, and the capacities of hospitals increase.&nbsp;</p> <p><em>Please stay tuned for important disclosure information at the conclusion of this video.</em></p> <p><strong>Christine Benz:</strong>&nbsp;Karen Andersen, who's a strategist in equity and credit research was with us&nbsp;<a href="https://www.morningstar.com/articles/972435/market-economic-implications-amid-latest-virus-news">three weeks ago</a>. She's back today and she's going to kick things off for us by providing an updated view on where we stand in terms of stopping the spread of the virus as well as the economic implications. So Karen will discuss developments that she and the team are seeing in terms of testing and vaccinations, therapies, as well as some of the equipment shortages that we've seen in the healthcare arena.</p> <p>Karen, please take it away.</p> <p><strong>Karen Andersen:</strong>&nbsp;Thanks Christine. Now that we have more information on how a coronavirus is spreading in different countries and more information on how governments are responding, my equity research colleague Preston Caldwell and I have updated our March 9 analysis. So our new report was published Tuesday, and it really tries to dive a little deeper into how this virus is affecting our health and our economy. So as far as health, we've refined our U.S. scenarios to get a month-by-month forecast of how the infection could spread and how widely the social distancing measures will be spread across the states.&nbsp;</p> <p>Just first, maybe a few updates on what we're doing to slow the spread of the virus right now. Almost half of Americans were under stay-at-home orders as at the end of March. And I believe that that dramatically increased in the past two days, as we've seen several more states issuing these kinds of orders. Our access to diagnostics is improving rapidly. So we now have more than a hundred thousand tests being performed each day in the U.S. so that brought us from March, I think, up to a million tests total. Both of these facts lead us to believe that our current efforts are allowing us to begin to reduce the number of cases possibly by early May and begin to slowly lift restrictions this summer, June and July. We do think we'll have confirmation of at least one effective treatment during the summer, which should give us more confidence even if we start to see some outbreaks again as we lift these restrictions, we won't see a replay of the shortages that we're currently seeing with ventilators in New York.&nbsp;</p> <p>Maybe just a little bit more on the treatment. So, the FDA actually just did sign off on March 28th on emergency use of two versions of an antimalarial drug to treat coronavirus. These drugs appear to act as antivirals in this case, and they have supportive data in some small studies so far. So hydroxychloroquine is being used widely in hospitals to help healthcare workers stay healthy and to treat patients as part of clinical trials or with this emergency approval. But there are also several other treatments that are now in clinical trials that we've updated in our new report. So Gilead's remdesivir remains the leading hope for an effective treatment, with data expected later this month from controlled studies in China, data from a handful of patients in different countries for remdesivir so far has been encouraging, but it's not definitive. So we're waiting for these studies that have a control arm to give us more indication. We model a 70% probability of approval for that drug.&nbsp;</p> <p>Two arthritis therapies are now also in clinical trials. These could help very sick patients with lung inflammation recover more quickly or avoid a ventilator, which is very important if we're facing these kinds of shortages. These therapies are widely available, and they could be quickly repurposed for coronavirus. And they only would require one dose that is being used in trials versus arthritis patients who typically require a dose every couple of weeks. Then in the long run, the pipeline is starting to shape up with the potential also for more-targeted drugs that are specifically designed against coronavirus by the end of the year and then vaccines in early 2021. I think JNJ was one of the latest firms that talked about accelerating their vaccine timelines, and they've guided now to an early 2021 time frame. That would be really roughly a one-year development time for a vaccine, and that would be at the faster end of that 12 to 18 months that a lot of companies have cited for coming up with a vaccine.</p> <p>The way I'm looking at this is that we will have waves of the virus and additional social distancing waves in the second half of the year, but not at the level of what we're doing right now, given the future availability of treatments. In addition, we'll have waves of new treatments after that, starting with repurposed drugs, Gilead's drug, targeted antibodies, and then ultimately a vaccine in 2021.&nbsp;</p> <p>Just very briefly turning to the economic impact. Our conclusions here are fairly similar to our previous report. We did increase the GDP impact we model for 2020, and we do now assume a 2.4% contraction in GDP in our base case. But we think the scope of the shutdown to disrupt the U.S. economy long-term is likely overrated. About 70% of GDP is actually from businesses that are mostly exempt from orders, and half of the businesses that aren't exempt can continue with remote operations. Also the fiscal stimulus should prevent a collapse on demand of the U.S. economy. That's our really our latest take on overall health and economic impact, Christine.</p> <p><strong>Benz:&nbsp;</strong>Karen, question for you: In terms of vaccines and therapies, let's talk about your sort of bear case if things don't unfold as you expect them to in the second half of the year.&nbsp;</p> <p><strong>Andersen:</strong>&nbsp;In a bear-case scenario, we do assume that there would be no effective treatment. And we also assume that we would be struggling a bit more to try to contain it even with this kind of first pass of social distancing measures. The other fact is that if we are struggling and there are no treatments, there's really only so long that we can try to hold on to this really aggressive shutdown of the country. I think that that probably would be limited to a few months as opposed to a year shutdown of the entire country.&nbsp;</p> <p>I do think that one thing that's important to remember, though, in this kind of scenario is the kind of tools that have been used in certain countries in Asia to prevent and control outbreaks. I'm thinking of countries like South Korea and Singapore. So what they do is they actually very aggressively trace contacts of those who become infected and then quarantine those who may have been exposed. And so now, just recently there's really been kind of an explosion in technology to help with this. And so there are various apps that can be used to track locations and then really determine who was close enough to someone who became infected that they need to self-quarantine. So this sort of information is really critical. Especially if we're in a situation where we've already contained the virus, and we're trying to emerge from a lockdown, and we don't have any kind of effective treatment.&nbsp;</p> <p>A big question here, though, is whether Americans are willing to accept the kind of privacy rights' violation issues that would come with this. I think one solution, though, could be to make these apps voluntary. And so if the situation remains really dire, I would hope that we would see a lot of folks volunteering to allow their maybe anonymized location data to be shared. So I think that even if we're really struggling with some of the social distancing measures, and even if we're not sure which treatment is best, I think there's probably a lot we can start to do, a progress we can make with technology, assuming Americans can get on board with this and start using their phones as something to help us fight the disease.</p> <p><strong>Benz:</strong>&nbsp;Karen, question for you about these ventilator shortages, which you briefly mentioned. Can you discuss your thoughts about how that will unfold in the coming months if these shortages aren't just limited to New York but other cities as well?</p> <p><strong>Andersen:</strong>&nbsp;Yeah, sure, Christine. New York, as of the data that we had on Tuesday, that was about 40% of U.S. cases and I think about 20% of all U.S. cases were in New York City alone. Having so many cases centered in one region or one city is frightening. There are so many limitations on what the healthcare system can handle from the number of ventilators, to even the number of healthcare workers trained to monitor patients on ventilators, to the number of ICU beds that these patients might need. We're seeing ventilator manufacturers trying to quickly increase capacity. Most of these companies are looking at something on the order of doubling their capacity. But this isn't really likely to come fast enough for this worst of the wave that's hitting us in April. But in our base- and bull-case scenarios, both of those scenarios, we think a ramped-up production of ventilators, potential new treatments, and better containment could all help improve the situation beginning in May.</p> <p>There are also a lot of creative ways that supply could be boosted faster. The FDA has already taken some steps here. They're allowing sleep apnea positive airway machines to be used in severe coronavirus patients. They're also using tube splitters, so that allows patients to share ventilators. Then also we've seen industries volunteer to make simplified ventilators that I wouldn't have really considered like auto industry or Dyson, the expert in vacuums. April will likely be very tough. But there are several ways that we can improve supply and reduce demand by having treatments beyond April.</p> <p><em>&copy;2020 Morningstar, Inc.. All Rights Reserved. The Morningstar name and logo are registered marks of Morningstar, Inc.</em></p> <p><em>This video contains certain forward-looking statements. We use words such as &ldquo;expects&rdquo;, &ldquo;anticipates&rdquo;, &ldquo;believes&rdquo;, &ldquo;estimates&rdquo;, &ldquo;forecasts&rdquo;, and similar expressions to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially and/or substantially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason.</em></p> <p><em>The information in this video is for informational purposes only and has no regard to the specific investment objectives, financial situation or needs of any specific recipient. This video is intended to provide information to assist investors in making their own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed and recommendations made herein may not be suitable for all investors: recipients must exercise their own independent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position.</em></p> <p><em>Opinions expressed are as of date this video was recorded; such opinions are subject to change without notice. Morningstar and its subsidiaries shall not be responsible for any trading decisions, damages, or other losses resulting from, or related to, the information, data, analyses or opinions or their use. The information, data, analyses, and opinions presented herein do not constitute investment advice, are provided solely for informational purposes and therefore are not an offer to buy or sell a security. Please note that references to specific securities or other investment options within this piece should not be considered an to purchase or sell that specific investment.</em></p> <p><em>It is important to note that investments in securities involve risk and will not always be profitable. There can be no assurance that any financial strategy will be successful.</em></p> <p><em>Christine Benz is an employee of Morningstar, Inc.</em></p> <p><em>Karen Andersen is an employee of Morningstar Research Services LLC. Investment research is produced and issued by subsidiaries of Morningstar, Inc. including, but not limited to, Morningstar Research Services LLC, registered with and governed by the U.S. Securities and Exchange Commission. The opinions expressed are given in good faith, are as of the date this video was recorded, and are subject to change without notice. The analysis presented are statements of opinions; they are not statements of fact. Analysts have made a reasonable effort to carefully research information contained in the video.</em></p> <p><em>The information on which the analysis is based has been obtained from sources believed to be reliable. While the data, statistics and information were obtained from sources it believes to be reliable, neither the Research group nor Morningstar, Inc. performs an audit or seeks independent verification of any of the data, statistics, and information it receives.</em></p> <p><em>The information contained in this video is the proprietary material of Morningstar. Reproduction, transcription, or other use, by any means, in whole or in part, without the prior written consent of Morningstar, is prohibited.</em></p>

Video Archive...

3 undervalued names in childcare
05/08/2020  Morningstar's Gareth James identifies three sector names trading at attractive discounts in an increasingly 'essential' sector.
Is the 60/40 portfolio dead?
05/08/2020  Reports of the strategy's demise are greatly exaggerated, says Morningstar's Christine Benz.
Why you should ignore a fund's yield
04/08/2020  Investors may assume a fund's yield to determine how much income it will pay, but it's not always so simple, warns Morningstar analyst Rajesh Yadav.
What are the right bonds for retirees today?
03/08/2020  It depends on your expectations and timeframe. Look at bonds as being portfolio stabilisers—sources of cash flow you can draw on when your equities are down, says Christine Benz.
3 top picks in rail, roads and utilities
28/07/2020  When utility stocks plunged during the onset of the pandemic Lazard Asset Management's Warryn Robertson knew it was time to jump in.
Infrastructure stocks in the covid era
24/07/2020  Lazard Asset Management's Warryn Robertson looks at how the pandemic has affected toll roads and airports and what the future of travel holds.
ESG stocks shine in covid-19 crisis
23/07/2020  Morningstar analyst Tancrede Fulop singles out a few companies that have performed well and also led the way in looking after staff. 
Stock-picking: Have you got what it takes?
21/07/2020  New stock-pickers are prone to lose money. Are the lessons worth the price? We ask Morningstar's Christine Benz.
Why mining stocks aren't yield plays
20/07/2020  Elevated iron ore prices have lifted mining company earnings to eye-watering levels but this doesn't make them income stocks, says Morningstar's Mat Hodge.
Commodity stocks riding high, but for how long?
17/07/2020  Local miners should deliver stellar fiscal 2020 results but such outperformance is unlikely to last, says Morningstar’s Mat Hodge.
The rise and rise of Amazon
17/07/2020  --
Should your portfolio shift when the economy slumps?
16/07/2020  How to make some upgrades during this down time.
Will Airbnb IPO or what?
16/07/2020  Covid-19 has made the intended public offering impossible, says Morningstar's Andrew Willis.
3 Japanese stock picks
15/07/2020  JPMorgan's Nicholas Weindling talks opportunities in Japan and reveals the stock that has been his largest holding for almost a decade
Small cap stocks: 'Inevitably, we see it all end in tears'
15/07/2020  The asset class has a habit of outperforming but Morningstar's Ross MacMillan sees signs of a bubble.
A trio of growth stocks
13/07/2020  Rachel Winter of UK fund manager Killik & Co talks payments, social media and investing in her monthly stock pick round-up
3 reasons healthcare is showing fit performance
09/07/2020  And what we expect to see moving forward.
Same old story: growth beats value
07/07/2020  Large growth maintains its supremacy in the Morningstar Style Box during a volatile first half for mutual funds. 
Nikko's 3 top Asian picks
06/07/2020  Nikko Asset Management's Peter Monson looks for strong sustainable returns and he sees that in Asian stocks that span financial exchanges, computer game makers and condiments suppliers.
How appealing are Asian stocks?
02/07/2020  China’s ongoing recovery from COVID-19 presents solid investment opportunities, says Nikko Asset Management.
'Unemployment will be higher, activity lower'
01/07/2020  Aviva Investors' Mark Robertson on the 'second wave', the widening gap between the West and China, portfolio protection and how covid has accelerated the tech revolution.
Smartwatches and luxury watches battle for your wrist
29/06/2020  Does the rise in smartwatches show that data, not diamonds, are a girl's best friend?
3 top picks in water and waste
26/06/2020  They may be 'boring' says Fidelity's Bertrand Lecourt but these names offer solid and long-term returns by delivering essential services.
Tapping opportunities in water and waste
25/06/2020  The growing consumption of water and the increased production of waste make these sectors compelling investments, says Fidelity's Bertrand Lecourt.
Dividends: ‘You have to be very active in stock selection’
23/06/2020  Yield can still be found among global healthcare, technology and consumer staples despite the dismal dividend outlook, says Janus Henderson’s Jane Shoemake.
Airlie went shopping during COVID sell-off
22/06/2020  COVID has given consumers the "fright of their lives" but this fund manager took the opportunity to scoop up bargain bluechips, says portfolio manager Matt Williams.
3 top picks: miner, insurer, fueler
19/06/2020  Mineral Resources, Medibank Private and Ampol are among Airlie Fund Management's preferred stocks, says portfolio manager Matt Williams.
Retail bonanza can’t last, warns Morningstar
16/06/2020  Investors shouldn’t project the pandemic-driven performance of JB HiFi and Harvey Norman too far into the future.
3 Aussie equities to watch
11/06/2020  Lazard Asset Management's Philipp Hofflin explains why mortgage processing, insurance and aluminium production are on his radar.
Are value stocks due for a comeback?
10/06/2020  Value investing has massively underperformed growth over the past decade. Christine Benz talks with Alex Bryan about the fundamental case for value.
3 top picks for a covid crisis
05/06/2020  Specialist consulting firms and chocolate bars. It's a disparate mix but Ned Bell of Bell Asset Management has good reason for seeing value in these sectors right now.
What the share market is missing
04/06/2020  Earnings results will be a rude awakening, says Ned Bell of Bell Asset Management, but there is nevertheless value among some global small- to mid-cap stocks.
The dividend balancing act
03/06/2020  Ensure your dividend-paying companies are more than attractive on the surface with these tips from Morningstar Canada's director of investment research, Ian Tam, CFA.
How dividend-paying stocks fit into retiree portfolios
01/06/2020  Christine Benz suggests retirees should take a balanced approach to these strategies.
Casino comeback and the uncertainty engulfing Seven West
29/05/2020  Most punters would prefer to lose money with their friends in a real casino than gambling online alone in their basement, says Brian Han.
The WFH reality-check for REITs
28/05/2020  Working from home means upheaval for office landlords but shopping mall owners are enjoying the end of hibernation, says Morningstar's Brian Han.
An undervalued, wide-moat name in healthcare
27/05/2020  Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
5 investing mistakes to avoid
20/05/2020  Christine Benz discusses pitfalls investors encounter as they navigate volatility and recovery.
Ugly housing outlook won’t last
19/05/2020  Adelaide Brighton, Amcor and Bingo should ride out the housing construction slump with relative ease, says Morningstar’s Grant Slade. 
3 stocks set to clean up
18/05/2020  The biggest corporate hygiene company you never heard of; Dettol's parent company; and a lab supplier are tipped to benefit post-coronavirus.
Greencape's three top picks
13/05/2020  Property listings, software for financial planners and AI machine-learning: Jonathan Koh has scoured the globe for opportunities.
Where to hunt when guidance statements get torn up
12/05/2020  Greencape Capital entered the downturn with a cash reserve that has allowed it to snare some essential services companies at bargain prices, says Jonathan Koh.
Investing basics: the hardest decision in investing
08/05/2020  When and how should you get back into equity markets after panic selling?
Weighing up Australia’s banks
07/05/2020  Bad debts and expected capital raising from three of the big four cloud the outlook for Aussie banks, says Morningstar's Nathan Zaia.
Surprises from Berkshire's annual meeting
05/05/2020  Morningstar's Gregg Warren discusses the meeting's cautious tone, Berkshire's lack of buying during the downturn, and unloading the airlines.
Banks will see out corona crisis
04/05/2020  Loan defaults, shaky house prices and a dividend pause - it's ugly in the short term but Nathan Zaia has long-term faith in Australia's banks.
What the pandemic means for Berkshire Hathaway
30/04/2020  Gregg Warren shares his thoughts on its valuation and more.
Netflix steals the show but for how long?
29/04/2020  What happens when the lockdown ends? The streaming giant may need to get some serious growth in international markets to make up for investor expectations. 
Unique, but normal: riding out this market crisis
27/04/2020  The markets follow patterns. We discuss ways to find your way to the upside of the current environment.
3 defensive utility stocks
23/04/2020  These utility stocks aren't the cheapest but have solid balance sheets and decent yield potential.
What in the world happened to oil prices?
22/04/2020  Amid such a painful downturn and the ensuing demand shock, it's crucial to consider companies that are in sound financial health, says Dave Meats.
'An apocalyptic asset': owning gold
21/04/2020  Gold can be a useful insurance policy for investment portfolios, says Morningstar analyst Kenneth Lamont, but it's not perfect
Energy crisis will be short-lived
20/04/2020  Will energy majors bounce back from the coronavirus-induced turmoil? You bet they will, says Mark Taylor and here are the names to watch.
What role do bonds play in an era of ultralow yields?
16/04/2020  Investors are right to be questioning bonds' role in their portfolios, but they still serve a useful purpose for many.
US tech sector now decently undervalued
14/04/2020  We examine how this sector handled the market turmoil and what to expect
Will energy stocks rise from the ashes?
09/04/2020  Investors' current concerns are justified, but vast long-term opportunities remain in this significantly undervalued sector.
Corona crisis threatens big four dividends
08/04/2020  The short-term may be scary but the major banks' long-term outlook will withstand the shock, says Morningstar's Nathan Zaia.
What to expect as the virus continues
08/04/2020  Christine Benz and Karen Andersen discuss Morningstar's latest views on stopping the spread of the virus as well as the economic implications.
In volatile markets, it's OK to chicken out
03/04/2020  Christine Benz explains why now isn't the time for grand gestures with your investments; instead, take a light touch to them.
Avoiding all eggs in the same basket
02/04/2020  Get the full effect of diversification by considering the correlation of your assets with these tips from Morningstar's Director of Investment Research, Ian Tam
Coronavirus: stock up on quality companies
01/04/2020  Retail and energy companies rank among Morningstar's sector picks, despite seeing some of the sharpest falls since coronavirus hit.
Is this 2008 all over again?
31/03/2020  Eric Jacobson explains why the banking system is not at the centre of the corona crisis, and in fact, is well positioned to be a tool to help solve it.
The critical reason to stay invested
30/03/2020  Why it's important to stay invested to capture critical months for your portfolio, with Morningstar's director of investment research, Ian Tam
How to avoid dividend cuts
27/03/2020  A wave of companies are expected to cut their dividends amid the coronavirus crisis. Morningstar's Dan Lefkovitz explains how to spot a firm that could its pay out.
Healthcare stocks still defensive, says Morningstar
26/03/2020  Respiratory specialist Fisher & Paykel Healthcare is among stocks now enticingly priced as the coronavirus hits markets and the Aussie dollar.
Cheap or nasty? Seven, Nine and Telstra
24/03/2020  A stock that’s heavily sold down isn’t always a screaming buy, as proven by this comparison of debt and other fundamentals among these well-loved companies.
Mining stocks offer price opportunity, dividend threat
20/03/2020  OZ Minerals, South32 and Iluka are among miners dipping into buy territory amid the coronavirus selloff but dividends are at risk, says Morningstar’s Mat Hodge.
Market, economic implications amid latest virus news
20/03/2020  Karen Andersen and Preston Caldwell give us their latest perspectives on healthcare and energy.
'The long-term bounceback will be strong'
17/03/2020  The coronavirus fallout is hurting but there should be a treatment by year end and the rebound will be strong, says Morningstar director of equities Johannes Faul. 
Taking control in time of corona
17/03/2020  In this timely Morningstar panel discussion, but Christine Benz and Andrew Lill provide  concrete tips on how curb your losses and put your money to use.
The importance of staying invested in volatile times
16/03/2020  Don't flee the market in a panic, but rather embrace the turmoil as an investment opportunity—you'll be better off in the long run.
‘A modest sell-off, not a panic’: Douglass on coronavirus fallout
14/03/2020  The Magellan co-founder insists now is not the time to ditch stocks for cash nor to buy bargains, and global businesses won’t turn their backs on China.
Avoid panic-selling: Douglass calls for calm
12/03/2020  Share market speculation is almost always a bad idea, and panic-selling stocks on coronavirus fears is an example of just that, warns Magellan boss.
Coronavirus and the market: our take
11/03/2020  We offer three takeaways and advice on staying true to your goals.
Hits and misses aplenty in first half 2020 - Part 2
10/03/2020  Consumer stock Breville and listed property firm Charter Hall were among the highest gainers after delivering results, while Mayne Pharma and Seven West saw the sharpest falls.
Hits and misses aplenty in first half 2020 - Part 1
09/03/2020  The interim reporting season served up a lesson in why investors shouldn't rely too heavily on company forecasts, says Morningstar's Peter Warnes
The best diversifiers for your equity portfolio
05/03/2020  Christine Benz discusses how to protect your portfolio from a stock-market sell-off.
Green bonds offer another side to ESG investing
05/03/2020  Investors are largely unaware of the role fixed income can play in expressing their views on social, environmental and governance issues.
ETF investing for the new decade: 4 trends to watch
02/03/2020  In only a decade, the value of Australia's ETF market has risen by almost 2000 per cent.
The new medical device company to watch
28/02/2020  Spray-on skin maker Avita Medical has a chance of becoming the new standard in burns treatment, says Morningstar's Nicolette Quinn. 
Helping financial advisers help investors
27/02/2020  Financial advice can deliver value but we must do a better job of showing what that is and measuring it, says Morningstar chief executive Kunal Kapoor.
'ESG is about building a portfolio for outperformance'
26/02/2020  Morningstar CEO Kunal Kapoor explains the importance of ESG investing and why it's not simply a matter of avoiding guns, smokes and booze.
Volatility is here to stay - here's what to do
25/02/2020  Morningstar's director of personal finance Christine Benz explains how investors - young and old - should navigate how the coronavirus, the US election and frothy stock prices.
Why mining dividends are a flash in the pan
24/02/2020  A near-record dividend payout from BHP reflects high iron ore prices and miners flush with cash, but these conditions won’t continue long-term, says Morningstar’s Mat Hodge.
The case for emerging market debt
20/02/2020  Lazard Asset Management's Arif Joshi demystifies emerging market debt and explains why it can offer excess yields.
Telstra faces Vodafone-TPG tie-up
18/02/2020  Morningstar equity analyst Brian Han reckons the Vodafone-TPG is a 75pc chance of proceeding but says there's a risk of overestimating its effect on Telstra.
CBA result puts dividend fears to bed, NAB on track
14/02/2020  Despite a profit dip there are many positives for CBA, including growth in mortgages and deposits and a strong balance sheet, says Morningstar equity analyst Nathan Zaia.
Doubts over James Hardie's bullish outlook
14/02/2020  The building materials supplier's long-term North American market share forecast is too ambitious, says Grant Slade 
Could Coronavirus hit China's luxury boom?
12/02/2020  Morningstar analyst Jelena Sokolova looks at the potential impact of the coronavirus on the luxury goods sector.
4 healthcare stocks attractive on valuation and ESG risk
10/02/2020  Morningstar's Karen Andersen explains how environmental, social and governance issues affect Big Pharma and biotech companies.
Coal case: why Whitehaven is a Best Idea
07/02/2020  Lower costs, higher prices, and demand from Asia: key reasons why the miner's shares are going cheap, says Morningstar director of equity research Mathew Hodge.
Two of Morningstar's Best Ideas
04/02/2020  Morningstar's Adam Fleck explains how his team decides on which names to recommend and reveals a stock that is trading at a 30 per cent discount to its fair value estimate.
Behind Morningstar's Global Best Ideas list
03/02/2020  A margin of safety and high analyst conviction are just two of the criteria behind this monthly selection of stocks for your watchlist, says Morningstar's Adam Fleck.
Morningstar's tribute to Jack Bogle
29/01/2020  There has never been anyone who has given more to investors and taken less in return than Jack Bogle.
Kraft Heinz on the comeback trail
23/01/2020  As the faltering firm works toward a turnaround, patient investors should consider its undervalued shares.
3 foodie stock picks
21/01/2020  Sarasin's Jeneiv Shah looks at three stocks across the food chain, including one company trying to stop cows from burping.
Morningstar's predictions for 2020
16/01/2020  A contraction in housing starts; advances in electric vehicle technology; Trump re-election; a rate cut; and another tough year for banks - just some of what's expected.
3 European stock picks for 2020
14/01/2020  Unloved cable companies and property firms provide some of the best opportunities in Europe, says T. Rowe Price's Dean Tenerelli. 
Best of 2019: Why Iluka is bucking the mining company trend
09/01/2020  In May 2019, Morningstar's Mat Hodge explained why this rare earths company provides a different exposure to consumer materials, and has a clear path to revenue growth.
Best of 2019: how to pick stocks like Warren Buffett
08/01/2020  In this Best of 2019 video, Morningstar director of investor education Karen Wallace reveals how Warren Buffet benefited from sniffing out companies with competitive advantages.